The United Kingdom and the United States have hammered out a major commercial pact that will maintain no duties on British pharmaceutical exports going into the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to increase expenditure on drugs through the public health system. This pledge guarantees that duties on these key goods will be held at nothing for a timeframe of three years.
This development comes after recent statements to hike duties on branded drug products, with figures discussed reaching double the cost.
"This deal between the United Kingdom strengthens the worldwide climate for new treatments and establishes long-overdue balance to transatlantic medicine commerce," a statement noted.
Trade Impact
Drugs represent one of the the United Kingdom's largest exports to the US, which is by far the primary destination for leading companies like GSK and AstraZeneca.
Statistics indicate that in the year to the end of September, the UK exported drugs valued at £11.1bn to the US. This amount made up nearly one-fifth of British export trade in that timeframe.
"This agreement safeguards work, boosts investment and paves the way for the UK to emerge as a international leader for medical research," the Business and Trade Secretary remarked.
Key NHS Changes
The deal includes several notable commitments from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to increase total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage drug companies must return to the NHS to prevent overspending will be restricted at 15%. In the past, refunds exceeded twenty percent.
Industry Background
The deal follows a ongoing tension between the drug companies and the UK government over drug pricing and NHS adoption.
These tensions were heightened by arguments that American customers were paying a premium for the identical medicines than patients in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been delayed or cancelled, while substantial investments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS needed to spend more on treatments, noting that its spending on drugs had declined as a percentage of its resources over the previous ten-year period.
